Rate My Professor Shigeki Aoki

Chiba University scientists identify glutamine metabolism and lysosomal function as key vulnerabilities in drug-tolerant persister cells, offering new directions for KRAS-driven cancer treatment.

Chiba University researchers identify glutamine metabolism and lysosomal function as key vulnerabilities in drug-tolerant persister cells surviving KRAS inhibitor therapy, paving the way for combination strategies to reduce cancer relapse.